Table.
Participants' and tumour characteristics at trial entry
| Surveillance (n=129) | Chemotherapy (n=131) | Total (n=260) | |
|---|---|---|---|
| Sex | |||
| Male | 83 (64%) | 93 (71%) | 176 (68%) |
| Female | 46 (36%) | 38 (29%) | 84 (32%) |
| Age group (years) | |||
| <50 | 5 (4%) | 5 (4%) | 10 (4%) |
| 50–59 | 24 (19%) | 19 (15%) | 43 (17%) |
| 60–69 | 52 (40%) | 50 (38%) | 102 (39%) |
| 70–79 | 40 (31%) | 51 (39%) | 91 (35%) |
| ≥80 | 8 (6%) | 6 (5%) | 14 (5%) |
| Median (IQR) | 66·5 (61·5–73·3) | 69·2 (57·8–75·0) | 68·5 (62·0–74·1) |
| WHO performance status | |||
| 0 | 85 (66%) | 90 (69%) | 175 (67%) |
| 1 | 43 (33%) | 40 (31%) | 83 (32%) |
| Missing data | 1 (1%) | 1 (1%) | 2 (1%) |
| Smoking status | |||
| Current | 14 (11%) | 13 (10%) | 27 (10%) |
| Previous | 67 (52%) | 70 (53%) | 137 (53%) |
| Never | 47 (36%) | 48 (37%) | 95 (37%) |
| Missing data | 1 (1%) | 0 (0%) | 1 (<1%) |
| Concomitant drugs | |||
| No | 27 (21%) | 25 (19%) | 52 (20%) |
| Yes | 102 (79%) | 105 (80%) | 207 (80%) |
| Antihypertensive | 51 (40%) | 60 (46%) | 111 (43%) |
| Analgesic | 30 (23%) | 21 (16%) | 51 (20%) |
| Antidiabetes | 11 (9%) | 15 (11%) | 26 (10%) |
| Anticoagulant | 19 (15%) | 9 (7%) | 28 (11%) |
| Antiangina | 7 (5%) | 7 (5%) | 14 (5%) |
| Other | 80 (62%) | 77 (59%) | 157 (60%) |
| Missing data | 0 (0%) | 1 (1%) | 1 (<1%) |
| Pathological T stage | |||
| pT2 | 30 (23%) | 44 (34%) | 74 (28%) |
| pT3 | 88 (68%) | 83 (63%) | 171 (66%) |
| pT4 | 11 (9%) | 4 (3%) | 15 (6%) |
| Nodal stage* | |||
| N0 | 118 (91%) | 118 (90%) | 236 (91%) |
| N1 | 7 (5%) | 8 (6%) | 15 (6%) |
| N2 | 4 (3%) | 4 (3%) | 8 (3%) |
| N3 | 0 (0%) | 1 (1%) | 1 (<1%) |
| GFR (mL/min) | |||
| 30–49 | 45 (35%) | 49 (37%) | 94 (36%) |
| ≥50 | 84 (65%) | 82 (63%) | 166 (64%) |
| Site of tumour | |||
| Renal pelvis | 44 (34%) | 47 (36%) | 91 (35%) |
| Ureter | 42 (33%) | 47 (36%) | 89 (34%) |
| Both | 40 (31%) | 37 (28%) | 77 (30%) |
| Missing data | 3 (2%) | 0 (0%) | 3 (1%) |
| Type of surgery | |||
| Open | 17 (13%) | 21 (16%) | 38 (15%) |
| Laparoscopic | 104 (81%) | 109 (83%) | 213 (82%) |
| Robotic | 4 (3%) | 1 (1%) | 5 (2%) |
| Other† | 1 (1%) | 0 (0%) | 1 (<1%) |
| Missing data | 3 (2%) | 0 (0%) | 3 (1%) |
| Microscopic margin status | |||
| Positive | 14 (11%) | 17 (13%) | 31 (12%) |
| Negative | 115 (89%) | 114 (87%) | 229 (88%) |
| Number of lymph nodes dissected | |||
| 0 | 92 (71%) | 86 (66%) | 178 (68%) |
| 1–3 | 21 (16%) | 25 (19%) | 46 (18%) |
| 4–9 | 6 (5%) | 6 (5%) | 12 (5%) |
| ≥10 | 6 (5%) | 3 (2%) | 9 (3%) |
| Missing data | 4 (3%) | 11 (8%) | 15 (6%) |
Data are n (%), unless otherwise stated. GFR=glomerular filtration rate.
*
Ascertained radiologically when pathological staging was not available.
†
Kidney and ureter freed laparoscopically and removed through an open incision at the iliac fossa.